Zepp Health Corporation, a global smartwatch maker, delivered strong Q1 2025 results, with 25% YoY shipment growth and 10% revenue increase, fueled by new launches like the Amazfit Active 2 and Bip 6. Despite an EPS dip to -$0.08, Zepp holds its rank as the seventh-largest smartwatch brand. The company is mitigating U.S. tariff risks through strategic shipment planning and Vietnam-based production, while its $179M net working capital dwarfs its $38M market cap, signaling undervaluation. Zepp ant...
Zepp Health Corporation (NYSE: ZEPP) saw a 28% stock rise since November 2024, with Q4-2024 revenue up 40% QoQ, driven by a 29% shipment surge. Despite a negative EPS, the T-Rex 3 and Amazfit Active 2 launches boosted growth. Ranking seventh in global smartwatch sales, Zepp leverages affordability amid tariffs, with $207M in net assets against a $51M market cap, signaling undervaluation.
This report provides an in-depth analysis of Zepp Health Corporation's (NYSE: ZEPP) Q3-2024 performance, highlighting a 4% QoQ revenue increase but a 49% YoY decline due to lower unit sales and product discontinuations. The report examines the launch of the T-Rex 3 smartwatch, supply chain constraints, and Zepp's competitive positioning in the global smartwatch market. It also discusses management's optimistic Q4 guidance, industry trends, and the valuation discrepancy between Zepp's market cap ...
Zepp Health Corporation (NYSE: ZEPP) experienced a significant revenue decline in Q2-2024, down 56% year-over-year, missing estimates due to lower-than-expected unit sales and the discontinuation of low-margin products. Despite the drop, cost-cutting measures led to an improvement in EBITDA, though it remained negative. The global smartwatch market also saw a 9% decline in shipments, impacting Zepp’s performance. However, the company is optimistic about a recovery in the second half of the year,...
Zepp Health specializes in smart wearables, providing advanced health tracking and fitness monitoring solutions. Despite a challenging Q1 2024, Zepp Health's strategic decisions and commitment to innovation are setting the stage for a promising year ahead. - Q1 2024 Performance: Revenue down 55% YoY, missing estimates by 7% due to lower unit sales. - Strategic Moves: Halted production of low-margin products, boosting gross profit for self-branded units by 33% YoY. - Market Position: Maintained ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.